Tags

Type your tag names separated by a space and hit enter

Effects of branched-chain amino acid-enriched nutrient for patients with hepatocellular carcinoma following radiofrequency ablation: a one-year prospective trial.
J Gastroenterol Hepatol 2010; 25(9):1550-5JG

Abstract

BACKGROUND AND AIM

This prospective control study examined whether supplementation with branched-chain amino acid (BCAA)-enriched nutrients can help maintain and improve residual liver function and nutritional status in cirrhotic patients with hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA).

METHODS

Subjects were 49 patients with hepatitis C-related HCC who underwent RFA. Two groups were formed: BCAA group (BCAA-enriched nutrient, aminoleban EN) and controls (standard diet only). Event-free survival rate, liver function tests, and Short Form (SF)-8 scores were evaluated in both groups before and one year after RFA. Energy metabolism using indirect calorimetry was measured before and after 3 months.

RESULTS

Complete data were obtained from 35 patients (BCAA group, n = 20; controls, n = 15). Six events (death, recurrence of HCC, rupture of esophageal varices and liver failure) occurred during the observation period, but frequencies of these events did not differ between groups. Event-free survival rate tended to be higher in the BCA group than in controls. Among the parameters of liver function, serum albumin level was only significantly increased over 6 months, and remained at similar values for one year (P < 0.05). SF-8 scores for general health, physical functioning, and social functioning were significantly elevated in the BCAA group (P < 0.05). Non-protein respiratory quotient was significantly improved in the BCAA group (P < 0.01).

CONCLUSION

Supplementation with BCAA-enriched nutrients for one year in cirrhotic patients with HCC after RFA therapy can perform safety and improve both nutritional state and quality of life.

Authors+Show Affiliations

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Morioka, Iwate, Japan. hikuro@iwate-med.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20796154

Citation

Kuroda, Hidekatsu, et al. "Effects of Branched-chain Amino Acid-enriched Nutrient for Patients With Hepatocellular Carcinoma Following Radiofrequency Ablation: a One-year Prospective Trial." Journal of Gastroenterology and Hepatology, vol. 25, no. 9, 2010, pp. 1550-5.
Kuroda H, Ushio A, Miyamoto Y, et al. Effects of branched-chain amino acid-enriched nutrient for patients with hepatocellular carcinoma following radiofrequency ablation: a one-year prospective trial. J Gastroenterol Hepatol. 2010;25(9):1550-5.
Kuroda, H., Ushio, A., Miyamoto, Y., Sawara, K., Oikawa, K., Kasai, K., ... Suzuki, K. (2010). Effects of branched-chain amino acid-enriched nutrient for patients with hepatocellular carcinoma following radiofrequency ablation: a one-year prospective trial. Journal of Gastroenterology and Hepatology, 25(9), pp. 1550-5. doi:10.1111/j.1440-1746.2010.06306.x.
Kuroda H, et al. Effects of Branched-chain Amino Acid-enriched Nutrient for Patients With Hepatocellular Carcinoma Following Radiofrequency Ablation: a One-year Prospective Trial. J Gastroenterol Hepatol. 2010;25(9):1550-5. PubMed PMID: 20796154.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of branched-chain amino acid-enriched nutrient for patients with hepatocellular carcinoma following radiofrequency ablation: a one-year prospective trial. AU - Kuroda,Hidekatsu, AU - Ushio,Akira, AU - Miyamoto,Yasuhiro, AU - Sawara,Kei, AU - Oikawa,Kanta, AU - Kasai,Kazuhiro, AU - Endo,Ryujin, AU - Takikawa,Yasuhiro, AU - Kato,Akinobu, AU - Suzuki,Kazuyuki, PY - 2010/8/28/entrez PY - 2010/8/28/pubmed PY - 2010/12/22/medline SP - 1550 EP - 5 JF - Journal of gastroenterology and hepatology JO - J. Gastroenterol. Hepatol. VL - 25 IS - 9 N2 - BACKGROUND AND AIM: This prospective control study examined whether supplementation with branched-chain amino acid (BCAA)-enriched nutrients can help maintain and improve residual liver function and nutritional status in cirrhotic patients with hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA). METHODS: Subjects were 49 patients with hepatitis C-related HCC who underwent RFA. Two groups were formed: BCAA group (BCAA-enriched nutrient, aminoleban EN) and controls (standard diet only). Event-free survival rate, liver function tests, and Short Form (SF)-8 scores were evaluated in both groups before and one year after RFA. Energy metabolism using indirect calorimetry was measured before and after 3 months. RESULTS: Complete data were obtained from 35 patients (BCAA group, n = 20; controls, n = 15). Six events (death, recurrence of HCC, rupture of esophageal varices and liver failure) occurred during the observation period, but frequencies of these events did not differ between groups. Event-free survival rate tended to be higher in the BCA group than in controls. Among the parameters of liver function, serum albumin level was only significantly increased over 6 months, and remained at similar values for one year (P < 0.05). SF-8 scores for general health, physical functioning, and social functioning were significantly elevated in the BCAA group (P < 0.05). Non-protein respiratory quotient was significantly improved in the BCAA group (P < 0.01). CONCLUSION: Supplementation with BCAA-enriched nutrients for one year in cirrhotic patients with HCC after RFA therapy can perform safety and improve both nutritional state and quality of life. SN - 1440-1746 UR - https://www.unboundmedicine.com/medline/citation/20796154/Effects_of_branched_chain_amino_acid_enriched_nutrient_for_patients_with_hepatocellular_carcinoma_following_radiofrequency_ablation:_a_one_year_prospective_trial_ L2 - https://doi.org/10.1111/j.1440-1746.2010.06306.x DB - PRIME DP - Unbound Medicine ER -